Cargando…

Development of a highly sensitive method for detection of JAK2V617F

BACKGROUND: Ph- myeloproliferative neoplasms (MPNs) represent a heterogeneous group of chronic diseases characterized by increased expansion of hematopoietic cells of the myeloid lineage. JAK2V617F, an activation mutation form of tyrosine kinase JAK2, is found in the majority of patients with MPNs....

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Anna H, Gao, Rufei, Zhao, Zhizhuang J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207960/
https://www.ncbi.nlm.nih.gov/pubmed/21985400
http://dx.doi.org/10.1186/1756-8722-4-40
_version_ 1782215586272509952
author Zhao, Anna H
Gao, Rufei
Zhao, Zhizhuang J
author_facet Zhao, Anna H
Gao, Rufei
Zhao, Zhizhuang J
author_sort Zhao, Anna H
collection PubMed
description BACKGROUND: Ph- myeloproliferative neoplasms (MPNs) represent a heterogeneous group of chronic diseases characterized by increased expansion of hematopoietic cells of the myeloid lineage. JAK2V617F, an activation mutation form of tyrosine kinase JAK2, is found in the majority of patients with MPNs. Studies have demonstrated that JAK2V617F can cause MPNs, and various methods have been developed to detect JAK2V617F for diagnostic purposes. However, a highly sensitive method is still needed for the earliest possible detection and for disease prevention and treatment. METHODS: In the present study, we developed a method dubbed restriction fragment nested allele-specific PCR (RFN-AS-PCR). The method consists of three steps: 1) initial amplification of DNA samples with PCR primers surrounding the JAK2V617F mutation site, 2) digestion of the PCR products with restriction enzyme BsaXI which only cleaves the wild type allele, and 3) detection of JAK2V617F by allele-specific PCR with nested primers. RESULTS: We tested the sensitivity of the method by using purified plasmid DNAs and blood cell DNAs containing known proportions of JAK2V617F. We were able to detect JAK2V617F with a sensitivity of 0.001%. We further analyzed blood cell DNA samples from 105 healthy donors with normal blood cell counts and found three JAK2V617F-positive cases, which would have remained undetected using a less sensitive method. CONCLUSIONS: We have developed a highly sensitive method that will allow for detection of JAK2V617F at a very early stage. This method may have major implications in diagnosis and prevention of MPNs and related diseases.
format Online
Article
Text
id pubmed-3207960
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32079602011-11-04 Development of a highly sensitive method for detection of JAK2V617F Zhao, Anna H Gao, Rufei Zhao, Zhizhuang J J Hematol Oncol Short Report BACKGROUND: Ph- myeloproliferative neoplasms (MPNs) represent a heterogeneous group of chronic diseases characterized by increased expansion of hematopoietic cells of the myeloid lineage. JAK2V617F, an activation mutation form of tyrosine kinase JAK2, is found in the majority of patients with MPNs. Studies have demonstrated that JAK2V617F can cause MPNs, and various methods have been developed to detect JAK2V617F for diagnostic purposes. However, a highly sensitive method is still needed for the earliest possible detection and for disease prevention and treatment. METHODS: In the present study, we developed a method dubbed restriction fragment nested allele-specific PCR (RFN-AS-PCR). The method consists of three steps: 1) initial amplification of DNA samples with PCR primers surrounding the JAK2V617F mutation site, 2) digestion of the PCR products with restriction enzyme BsaXI which only cleaves the wild type allele, and 3) detection of JAK2V617F by allele-specific PCR with nested primers. RESULTS: We tested the sensitivity of the method by using purified plasmid DNAs and blood cell DNAs containing known proportions of JAK2V617F. We were able to detect JAK2V617F with a sensitivity of 0.001%. We further analyzed blood cell DNA samples from 105 healthy donors with normal blood cell counts and found three JAK2V617F-positive cases, which would have remained undetected using a less sensitive method. CONCLUSIONS: We have developed a highly sensitive method that will allow for detection of JAK2V617F at a very early stage. This method may have major implications in diagnosis and prevention of MPNs and related diseases. BioMed Central 2011-10-10 /pmc/articles/PMC3207960/ /pubmed/21985400 http://dx.doi.org/10.1186/1756-8722-4-40 Text en Copyright ©2011 Zhao et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Zhao, Anna H
Gao, Rufei
Zhao, Zhizhuang J
Development of a highly sensitive method for detection of JAK2V617F
title Development of a highly sensitive method for detection of JAK2V617F
title_full Development of a highly sensitive method for detection of JAK2V617F
title_fullStr Development of a highly sensitive method for detection of JAK2V617F
title_full_unstemmed Development of a highly sensitive method for detection of JAK2V617F
title_short Development of a highly sensitive method for detection of JAK2V617F
title_sort development of a highly sensitive method for detection of jak2v617f
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3207960/
https://www.ncbi.nlm.nih.gov/pubmed/21985400
http://dx.doi.org/10.1186/1756-8722-4-40
work_keys_str_mv AT zhaoannah developmentofahighlysensitivemethodfordetectionofjak2v617f
AT gaorufei developmentofahighlysensitivemethodfordetectionofjak2v617f
AT zhaozhizhuangj developmentofahighlysensitivemethodfordetectionofjak2v617f